^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

TT11X

i
Other names: TT11X, TT 11X, Allogeneic CD30.CAR-EBVST, Allogeneic CD30-Chimeric Antigen Receptor Epstein-Bar Virus-Specific T cells, TT-11X
Associations
Company:
Tessa Therap
Drug class:
CD30-targeted CAR-T immunotherapy
Associations
2ms
Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas (clinicaltrials.gov)
P1, N=90, Not yet recruiting, Baylor College of Medicine | Initiation date: Jun 2024 --> Jan 2025
Trial initiation date • Virus specific T cells
|
TT11X
11ms
New P1 trial
|
TT11X
1year
Enrollment change • Trial withdrawal • Virus specific T cells
|
ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8)
|
ALK positive • TNFRSF8 positive • ALK negative
|
TT11X
over1year
Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes in Relapsed or Refractory CD30-Positive Lymphomas (clinicaltrials.gov)
P1, N=18, Not yet recruiting, Baylor College of Medicine | Trial completion date: Jun 2038 --> Jun 2040 | Trial primary completion date: Jun 2023 --> Jun 2025
Trial completion date • Trial primary completion date • Virus specific T cells
|
ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8)
|
ALK positive • TNFRSF8 positive • ALK negative
|
TT11X
2years
Humanized CD30 chimeric antigen receptor T cells with a novel 4-1BB derived spacer have improved activity and safety against CD30-positive lymphomas​ (SITC 2022)
Humanized CD30.CARs combined with the 4-1BB-derived spacer did not exhibit any nonspecific interactions with CD16+ immune cells, while displaying superior efficacy in vitro , better persistence in vivo in various humanized mouse models, and more importantly an improved safety profile in a leukemia model with high tumor burden. Conclusions Our re-engineered CD30.CAR construct, consisting of a humanized CD30.CAR and a 4-1BB-derived spacer, is likely to improve allogeneic CD30.CAR EBVST performance.
Clinical • CAR T-Cell Therapy
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 positive • TNFRSF8 expression
|
TT11X
over2years
Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas (clinicaltrials.gov)
P1, N=18, Recruiting, Baylor College of Medicine | Trial primary completion date: Jun 2022 --> Jun 2025
Trial primary completion date
|
ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8)
|
ALK positive • TNFRSF8 positive • ALK negative
|
TT11X
over3years
Clinical • New P1 trial
|
ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8)
|
ALK positive • TNFRSF8 positive • ALK negative
|
TT11X
4years
Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas (clinicaltrials.gov)
P1, N=18, Recruiting, Baylor College of Medicine | Not yet recruiting --> Recruiting
Clinical • Enrollment open
|
ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8)
|
ALK positive • TNFRSF8 positive • ALK negative
|
TT11X
over4years
Clinical • New P1 trial
|
ALK (Anaplastic lymphoma kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8)
|
ALK positive • TNFRSF8 positive • ALK negative
|
TT11X